

# PSILOCYBIN for DEPRESSION Study

If you are between the ages of 21 and 65, you may be eligible for a clinical trial examining psilocybin and depression.

**Dr. Keith Heinzerling** and researchers at the Treatment & Research In Psychedelics (TRIP) Program at Pacific Neuroscience Institute want to find out if a drug called psilocybin can be safe and effective for treating Major Depressive Disorder (MDD). Psilocybin is an investigational drug. This means that the US Food and Drug Administration (FDA) has not approved psilocybin for the treatment of MDD, and psilocybin can only be given in a research study.

## What will happen during the study?

You will receive a single capsule of either psilocybin or a placebo. The placebo in this study is niacin (Vitamin B3).

Participation involves:

- Blood and urine samples
- Physical examinations
- An ECG
- Psychological evaluations
- Weaning off medications and/or psychotherapy for your depression under the close supervision of a study psychiatric provider (as applicable)

## How much time will I spend on the study?

Participation lasts approximately 3 months and will include around 13 study visits. Most visits will last about 2 hours; however, two visits could last up to 8-10 hours.

Participants will receive monetary compensation.

**PACIFIC  
NEUROSCIENCE  
INSTITUTE®**

If you are interested and want to learn more, please contact the research team at:

**310-582-7611** or visit **[pacifctrip.org](http://pacifctrip.org)**